Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.45%
SPX
-0.35%
IXIC
-0.14%
FTSE
-0.23%
N225
+0.21%
AXJO
-0.45%
Cashu Logo
⌘K
Log In
HomeWatchlistNewsSignals

HROW is now overvalued and could go down -48%

Aug 19, 2025, 12:01 PM
12.73%
What does HROW do
Harrow, headquartered in Nashville, Tennessee, develops and sells innovative ophthalmic medications and operates ImprimisRx, employing 315 staff since its IPO on February 8, 2013. The company markets various prescription products, including VIGAMOX and IHEEZO.
Based on our analysis, Harrow has received an overvalued rating of 1 out of 5 stars from Cashu, primarily due to its financial performance relative to industry standards. One critical ratio is the Price-to-Book (PB) Ratio, which stands at 17.15 compared to the sector average of 2.71. This high PB Ratio suggests that investors are paying significantly more for each dollar of net assets than is typical in the industry, indicating potential overvaluation. The company also shows a negative Net Profit Margin of -8.76, while the sector average is -137.57. Although Harrow's margin is less negative than its peers, it still reflects an inability to generate profits, raising concerns about its operational efficiency. Another concerning metric is the Return on Equity (ROE) Ratio, which is at -25.10 versus the sector average of -76.41. A negative ROE indicates that the company is not generating returns on shareholders' equity, suggesting poor financial health and management efficiency. Lastly, the Return on Assets (ROA) Ratio is reported at -4.49, compared to the sector's -47.59. While Harrow is outperforming the sector in this area, the negative value still indicates inefficient use of assets to generate earnings. These financial ratios collectively highlight concerns about Harrow's valuation and operational performance, leading to its overvalued rating. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.